HIV Detail Information

Dolutegravir (ID: DG00011) Resistance Data of HIV
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Aberration of the Drug's Therapeutic Target (ADTT) Click to Show/Hide
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.K14R+p.S24N+p.V31I+p.M50I+p.L74I+p.A91E+p.L101I+p.T112V+p.G118R+p.S119R+p.T124A+p.T125A+p.A133T+p.G134N+p.I135V+p.K136T+p.E138K+p.V165I+p.V201I+p.T206S+p.T218I+p.L234I+p.S283D
Missense mutation 12.7 Potential low-level resistance [1]
p.E11D+p.K14R+p.S24N+p.V31I+p.M50I+p.L74I+p.A91E+p.L101I+p.T112V+p.G118R+p.S119R+p.T124A+p.T125A+p.A133T+p.G134N+p.I135V+p.K136T+p.V165I+p.V201I+p.T206S+p.T218I+p.L234I+p.S283D
Missense mutation 15.5 Low-level resistance [1]
Resistant Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
In Vitro Model BL21 cells Cerebrospinal fluid Homo sapiens (Human) CVCL_M639
Experiment for
Molecule Alteration		 Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.S24G+p.D25E+p.S39C+p.I60IM+p.L63I+p.T97A+p.L101I+p.S119SR+p.T124N+p.T125A+p.I135V+p.E138T+p.G140S+p.Q148H+p.M154I+p.V165I+p.V201I+p.V259VI
Missense mutation 100 High-level resistance [2]
Resistant Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q202H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6T+p.K7E+p.S17N+p.V54I+p.I72V+p.L74M+p.V79I+p.T97A+p.L101I+p.I113L+p.S119R+p.T122I+p.T124N+p.T125A+p.E138K+p.G140A+p.I141AT+p.S147SG+p.Q148R+p.K156N+p.I203M+p.I208M+p.L234V+p.D253E
Missense mutation 100 High-level resistance [2]
Resistant Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q203H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.E69ED+p.E138K+p.G140S+p.Q148H+p.M154I+p.N155H+p.V201I
Missense mutation 100 High-level resistance [2]
Resistant Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q204H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6DE+p.E11D+p.S17T+p.A23V+p.V37I+p.I60IM+p.K71Q+p.A91AS+p.T97A+p.K111A+p.S119R+p.T124TN+p.T125Q+p.E138T+p.G140S+p.Q148H+p.I203M
Missense mutation 100 High-level resistance [3]
Resistant Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6DE, E11D, S17T, A23V, V37I, I60IM, K71Q, A91AS, T97A, K111A, S119R, T124TN, T125Q, E138T, G140S, Q148H, I203M.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10DG+p.E11D+p.V31I+p.S119P+p.T122I+p.T125A+p.V126M+p.A128AT+p.G140GS+p.V151VI+p.N155H+p.G163E+p.S195C+p.L234V+p.D279DN
Missense mutation 14 Potential low-level resistance [4]
Resistant Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E10DG, E11D, V31I, S119P, T122I, T125A, V126M, A128AT, G140GS, V151VI, N155H, G163E, S195C, L234V, D279DN.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E138K+p.G140A+p.Q148R
Missense mutation 13 Potential low-level resistance [5]
Resistant Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138K, G140A, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L63I+p.I73V+p.L74I+p.E96D+p.L101I+p.T112I+p.G140S+p.Q148H+p.I208L+p.D232E+p.L234LF
Missense mutation 15 Low-level resistance [4]
Resistant Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63I, I73V, L74I, E96D, L101I, T112I, G140S, Q148H, I208L, D232E, L234LF.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.T97A+p.L101I+p.T112M+p.S119P+p.T122I+p.T124N+p.T125A+p.G140S+p.Q148H
Missense mutation 66 High-level resistance [3]
Resistant Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, T97A, L101I, T112M, S119P, T122I, T124N, T125A, G140S, Q148H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.E138K+p.Q148K
Missense mutation 34 Intermediate resistance [5]
Resistant Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, E138K, Q148K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A+p.G118R
Missense mutation 11 Potential low-level resistance [6]
Resistant Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, G118R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140S+p.Q148K+p.D232N
Missense mutation 45 Intermediate resistance [7]
Resistant Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E296Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
       Aberration of the Drug's Therapeutic Target (ADTT) Click to Show/Hide
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.G118R+p.E138K+p.V151I+p.L234V
Missense mutation 8 Susceptible [1]
p.I72V+p.I113V+p.E138K+p.V151I+p.L234V
Missense mutation 0.8 Susceptible [1]
p.I72V+p.I113V+p.G118R+p.V151I+p.L234V
Missense mutation 8.2 Susceptible [1]
p.H51Y+p.I72V+p.I113V+p.V151I+p.L234V
Missense mutation 1.4 Susceptible [1]
p.E11D+p.K14R+p.S24N+p.V31I+p.M50I+p.L74I+p.A91E+p.L101I+p.T112V+p.S119R+p.T124A+p.T125A+p.A133T+p.G134N+p.I135V+p.K136T+p.E138K+p.V165I+p.V201I+p.T206S+p.T218I+p.L234I+p.S283D
Missense mutation 0.8 Susceptible [1]
p.E11D+p.K14R+p.S24N+p.V31I+p.M50I+p.H51Y+p.L74I+p.A91E+p.L101I+p.T112V+p.S119R+p.T124A+p.T125A+p.A133T+p.G134N+p.I135V+p.K136T+p.V165I+p.V201I+p.T206S+p.T218I+p.L234I+p.S283D
Missense mutation 1.4 Susceptible [1]
p.S17N+p.M50L+p.I72V+p.Q95QH+p.T112V+p.I113V+p.T124A+p.T125A+p.G134D+p.V201I+p.Q221QKR+p.L234I+p.D256E
Missense mutation 1 Susceptible [8]
p.I5V+p.S17N+p.M50L+p.E69G+p.I72V+p.T112I+p.I113V+p.T124A+p.T125A+p.T174A+p.V201I+p.T218I+p.L234I+p.D256E
Missense mutation 0.3 Susceptible [8]
p.K42Q+p.L101I+p.T112V+p.T124A+p.T125A+p.K136Q+p.G163R+p.V201I+p.L234I+p.R269K+p.D278A+p.S283G
Missense mutation 0.2 Susceptible [8]
p.K14R+p.V31I+p.I72V+p.T112V+p.I113V+p.T124A+p.T125A+p.G134N+p.I135V+p.D167E+p.V201I+p.T206S+p.I208L+p.N222K+p.L234I+p.A265V+p.R269K+p.S283G
Missense mutation 0.7 Susceptible [8]
p.K14R+p.V31I+p.L74I+p.L101I+p.T112V+p.T124A+p.T125A+p.G134N+p.I135V+p.K136T+p.H171Q+p.V201I+p.T206S+p.I208M+p.T218I+p.L234I+p.A265V+p.R269K+p.D286N
Missense mutation 0.1 Susceptible [8]
p.L101I+p.T122I+p.T124N+p.A265V
Missense mutation 1 Susceptible [8]
p.S17N+p.I72V+p.I84V+p.T124A+p.M154I+p.K173R
Missense mutation 0.8 Susceptible [8]
p.S17N+p.L28I+p.P30A+p.I84L+p.S119T+p.T124A+p.K136Q+p.V165I+p.I200T+p.V201I+p.K211R+p.T218I+p.L234V+p.D256E+p.S283G
Missense mutation 0.4 Susceptible [8]
p.L101I+p.T125A+p.I135V+p.D167DE+p.G193R+p.V201I+p.I208L+p.K211T+p.A265V+p.S283G
Missense mutation 1.4 Susceptible [8]
p.E11D+p.D25E+p.V31I+p.F100Y+p.L101I+p.T112V+p.S119P+p.K136Q+p.V201I+p.T218I+p.L234I+p.A265V+p.R269K+p.D278A+p.S283G
Missense mutation 0.8 Susceptible [8]
p.K14R+p.A21T+p.A23V+p.S39N+p.I72V+p.T112V+p.T124A+p.T125A+p.G134N+p.I135V+p.K136R+p.D167E+p.V201I+p.L234I+p.S283G
Missense mutation 0.1 Susceptible [8]
p.K14R+p.A21T+p.V31I+p.V32I+p.M50I+p.I72V+p.T112V+p.T124A+p.T125A+p.G134N+p.I135V+p.K136R+p.D167E+p.V201I+p.T206S+p.L234I+p.S283G
Missense mutation 0.2 Susceptible [8]
p.V88I+p.M154I
Missense mutation 0.3 Susceptible [8]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
In Vitro Model BL21 cells Cerebrospinal fluid Homo sapiens (Human) CVCL_M639
Experiment for
Molecule Alteration		 Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Amino acid changes in IN may contribute to dolutegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R20K+p.V31I+p.L45I+p.L101I+p.I135IV+p.N155H+p.E157Q+p.K160Q+p.V201I+p.K215N+p.A265V
Missense mutation 1.7 Susceptible [9]
p.R20K+p.V31I+p.L45I+p.L101I+p.K111KR+p.I135IV+p.E157Q+p.K160Q+p.V201I+p.K215N+p.A265AV
Missense mutation 1.1 Susceptible [9]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 RT-PCR; Sequencing assay
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Five mutations (A49P, L68FL, T97A, E138k and L234V) were implicated in emergent dolutegravir resistance, with a concomitant severe compromise in viral replicative capacity.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.A23T+p.S24G+p.D25E+p.L28I+p.I72V+p.T124A+p.Q148R+p.V165I+p.L172LF+p.H183HP+p.Q209QP+p.A239AT
Missense mutation 0.5 Susceptible [2]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q186H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.S39R+p.L45V+p.M50ML+p.T66A+p.V75I+p.L101I+p.T124A+p.K127R+p.S147SG+p.G163K+p.V201I
Missense mutation 0.7 Susceptible [2]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q187H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K7KR+p.S17N+p.I72V+p.I84L+p.T97A+p.L101I+p.T112I+p.S119P+p.T122I+p.T124N+p.T125A+p.K136Q+p.Y143R+p.V201I+p.A205S+p.K211R+p.T218L+p.L234V+p.D256E+p.I268L+p.D270H
Missense mutation 1 Susceptible [2]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q188H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G59D+p.I60V+p.E138K+p.Q148R+p.K173R+p.T218S+p.S230N+p.M275S+p.C280S
Missense mutation 1 Susceptible [2]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q189H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.S24H+p.V31I+p.L68I+p.I73V+p.E92Q+p.L101I+p.T112V+p.S119T+p.T124G+p.T125A+p.G134N+p.K136T+p.V165I+p.V201I+p.T206S+p.L234I+p.D256E+p.S283G
Missense mutation 1.2 Susceptible [2]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q190H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.L101V+p.T112I+p.T125V+p.N155H+p.E157Q+p.K160Q+p.G193E+p.S230N+p.L234I+p.A265V+p.D279G
Missense mutation 2.1 Susceptible [2]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q191H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.R20K+p.E92Q+p.V201I+p.K211R+p.S230SN+p.D232E+p.D256E
Missense mutation 2.6 Susceptible [2]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q192H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.M154L+p.N155H+p.V201I+p.D232N+p.L242LF
Missense mutation 2.7 Susceptible [2]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q193H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.S17T+p.S39N+p.I72V+p.S119P+p.T122I+p.T124N+p.T125A+p.V151I+p.N155H+p.N222K+p.P261A
Missense mutation 3.1 Susceptible [2]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q194H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.V31I+p.V32I+p.L45Q+p.L101I+p.T112V+p.T125A+p.G134N+p.I135V+p.K136T+p.Y143C+p.V201I+p.T206S+p.S230R+p.L234I+p.N254NS+p.R269K+p.D270H
Missense mutation 3.5 Susceptible [2]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q195H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.R20K+p.M50I+p.V77A+p.L101I+p.T112I+p.T124A+p.T125A+p.K136Q+p.G193E+p.V201I+p.T206S+p.T218L+p.I220V+p.L234V+p.D256E+p.R263K+p.D279G+p.S283G
Missense mutation 3.5 Susceptible [2]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q196H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.V31I+p.T97A+p.L101I+p.T112V+p.S119R+p.T124A+p.T125S+p.G134N+p.K136T+p.N155H+p.V165I+p.V201I+p.T206S+p.Y227F+p.L234I+p.S255N+p.D256E+p.S283G
Missense mutation 4 Susceptible [2]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q197H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.V31I+p.G70R+p.I84V+p.L101I+p.S119P+p.T122I+p.N155H+p.G163E+p.V201I+p.D256E
Missense mutation 4.4 Susceptible [2]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q198H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.D25E+p.S119G+p.T122I+p.T124N+p.T125A+p.M154I+p.N155H+p.K156R+p.T206S+p.T218S
Missense mutation 4.5 Susceptible [2]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q199H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.S17C+p.L68V+p.L101I+p.T124N+p.T125A+p.I135V+p.G140A+p.Q148R+p.D253E+p.V281M
Missense mutation 7.3 Susceptible [2]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q200H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.K14R+p.S17T+p.V31I+p.L45V+p.A91S+p.L101I+p.T124A+p.E138Q+p.G140C+p.Q148R+p.V151I+p.K219N+p.N222K+p.L234I+p.V259I
Missense mutation 8 Susceptible [2]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q201H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.V151I+p.L234V+p.R263K
Missense mutation 2.1 Susceptible [10]
p.K14R+p.D25E+p.V31I+p.L45S+p.I72V+p.E96D+p.F100Y+p.L101I+p.T112V+p.T124A+p.T125A+p.K136Q+p.V201I+p.K219N+p.N222K+p.L234I+p.R263K+p.A265V+p.R269K+p.D278A
Missense mutation 3.3 Susceptible [10]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Our results show that the R263k substitution decreased HIV-1 subtype C susceptibility to DTG and EVG by 3.3 and 50-fold, respectively. In subtype B, R263k conferred a somewhat lesser degree of drug resistance, that is, 2.1 and 25-fold decreases in susceptibility to DTG and EVG, respectively. R263k did not confer resistance against RAL in HIV-1 subtype C in accordance with results for subtype B.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.V32I+p.I36V+p.D41G+p.M50L+p.I72V+p.L101I+p.T124N+p.T125A+p.I135V+p.V201I+p.I208L+p.D256E
Missense mutation 1.1 Susceptible [11]
p.S17N+p.V32I+p.I36V+p.D41G+p.M50L+p.I72V+p.L101I+p.T124N+p.T125A+p.I135V+p.Q148N+p.V201I+p.I208L+p.D256E
Missense mutation 0.7 Susceptible [11]
p.S17N+p.V32I+p.I36V+p.D41G+p.M50L+p.I72V+p.L101I+p.T124N+p.T125A+p.I135V+p.G140S+p.Q148N+p.V201I+p.I208L+p.D256E
Missense mutation 0.5 Susceptible [11]
p.I72V+p.I113V+p.G140S+p.Q148H+p.V151I+p.L234V
Missense mutation 3.4 Susceptible [11]
p.I72V+p.I113V+p.Q148H+p.V151I+p.L234V
Missense mutation 0.6 Susceptible [11]
p.I72V+p.I113V+p.G140S+p.Q148N+p.V151I+p.L234V
Missense mutation 0.6 Susceptible [11]
p.I72V+p.I113V+p.Q148N+p.V151I+p.L234V
Missense mutation 0.6 Susceptible [11]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 PCR; DNA sequencing assay
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Q148N, a novel integrase inhibitor resistance mutation associated with low-level reduction in elvitegravir susceptibility.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.A128T
Missense mutation 1.1 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included A128T.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.A91E
Missense mutation 0.7 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included A91E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D25E+p.I72V+p.G140S+p.Q148H+p.V151I+p.K211R+p.K215N
Missense mutation 3 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D25E, I72V, G140S, Q148H, V151I, K211R, K215N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6E+p.E10D+p.A23S+p.V31I+p.L101I+p.T124A+p.K156N+p.V201I+p.M275V
Missense mutation 1 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, E10D, A23S, V31I, L101I, T124A, K156N, V201I, M275V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6E+p.E10D+p.A23S+p.V31I+p.L101I+p.T124A+p.V151I+p.N155H+p.K156N+p.V201I+p.D232N+p.M275V
Missense mutation 2 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, E10D, A23S, V31I, L101I, T124A, V151I, N155H, K156N, V201I, D232N, M275V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6E+p.E10D+p.V31I+p.L101I+p.T124A+p.K156N+p.V201I+p.V249VI+p.M275V
Missense mutation 1 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, E10D, V31I, L101I, T124A, K156N, V201I, V249VI, M275V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6E+p.K14KR+p.S17N+p.R20K+p.D25E+p.S39C+p.L45X+p.T97TA+p.L101I+p.S119SR+p.T124A+p.V151VI+p.N155NH+p.K160T+p.G163GR+p.V201I+p.K211R+p.D288N
Missense mutation 3.7 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D6E, K14KR, S17N, R20K, D25E, S39C, L45X, T97TA, L101I, S119SR, T124A, V151VI, N155NH, K160T, G163GR, V201I, K211R, D288N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E138A
Missense mutation 0.9 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E138K+p.Q148K
Missense mutation 7 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138K, Q148K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E138K+p.Q148R
Missense mutation 2.1 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138K, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E138K
Missense mutation 0.9 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E157K
Missense mutation 1.6 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E157K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E157Q
Missense mutation 1.1 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E157Q.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E170A
Missense mutation 1 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E170A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E92G
Missense mutation 1 Susceptible [13]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E92Q+p.G140A
Missense mutation 2.3 Susceptible [5]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92Q, G140A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E92Q+p.N155H
Missense mutation 1.9 Susceptible [13]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92Q, N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E92Q+p.Q148R
Missense mutation 4.2 Susceptible [13]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92Q, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E92Q
Missense mutation 1.3 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92Q.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G118R
Missense mutation 6.1 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G118R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G140A+p.Q148R
Missense mutation 2.8 Susceptible [5]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140A, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G140A
Missense mutation 0.6 Susceptible [5]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G140C
Missense mutation 0.5 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140C.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G140E
Missense mutation 0.9 Susceptible [5]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G140S+p.Q148H
Missense mutation 4.1 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140S, Q148H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G140S+p.Q148R
Missense mutation 4 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140S, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G140S
Missense mutation 0.8 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140S.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G163K
Missense mutation 0.9 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G163K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G4GR+p.R20K+p.T97A+p.T112V+p.I113V+p.T125A+p.Y143YC+p.H171Q+p.Y194YH+p.I200M+p.I203M+p.S230R
Missense mutation 1 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G4GR, R20K, T97A, T112V, I113V, T125A, Y143YC, H171Q, Y194YH, I200M, I203M, S230R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G70R
Missense mutation 1.1 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G70R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.H51Y+p.I72V+p.I113V+p.L234V+p.R263K
Missense mutation 7 Susceptible [14]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included H51Y, I72V, I113V, L234V, R263K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.H51Y+p.I72V+p.I113V+p.L234V
Missense mutation 1 Susceptible [14]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included H51Y, I72V, I113V, L234V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.H51Y
Missense mutation 1.2 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included H51Y.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72A+p.N155H
Missense mutation 1.1 Susceptible [5]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72A, N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72A
Missense mutation 0.6 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72N
Missense mutation 0.6 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72T
Missense mutation 0.9 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72T.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72V+p.I113V+p.L234V+p.R263K
Missense mutation 2 Susceptible [14]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72V, I113V, L234V, R263K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K7R+p.S17N+p.V31I+p.T97A+p.L101I+p.T112A+p.T125A+p.Y143R+p.M154I+p.V201I
Missense mutation 1 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K7R, S17N, V31I, T97A, L101I, T112A, T125A, Y143R, M154I, V201I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L234F
Missense mutation 1.2 Susceptible [5]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L234F.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L45Q+p.T115H
Missense mutation 1.5 Susceptible [5]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L45Q, T115H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L68I
Missense mutation 0.7 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L68I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L68V
Missense mutation 0.6 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L68V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74I+p.T97A
Missense mutation 0.7 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74I, T97A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74I
Missense mutation 1 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M+p.S119P
Missense mutation 0.7 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, S119P.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M+p.S119R
Missense mutation 0.9 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M+p.T97A+p.S119G
Missense mutation 0.5 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A, S119G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M+p.T97A+p.S119P
Missense mutation 0.6 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A, S119P.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M+p.T97A+p.S119R
Missense mutation 0.9 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M+p.T97A+p.S119T
Missense mutation 0.5 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A, S119T.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M+p.T97A
Missense mutation 0.6 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M50I+p.T97A
Missense mutation 0.7 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M50I, T97A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.N155H
Missense mutation 1.8 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.NULL
Missense mutation 1 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included NULL.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.P145S
Missense mutation 0.3 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included P145S.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q146I
Missense mutation 2.2 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q146I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q146K
Missense mutation 0.8 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q146K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q146L
Missense mutation 1.3 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q146L.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q146P
Missense mutation 0.5 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q146P.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q146R
Missense mutation 1.4 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q146R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q148H
Missense mutation 0.5 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q148K
Missense mutation 1.5 Susceptible [13]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q148R+p.N155H
Missense mutation 6.4 Susceptible [13]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148R, N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q148R
Missense mutation 1.1 Susceptible [13]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q95K
Missense mutation 1.1 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q95K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q95R
Missense mutation 1 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q95R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R263K
Missense mutation 1.7 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R263K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S119R+p.F121Y
Missense mutation 1.1 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S119R, F121Y.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S147G
Missense mutation 1.1 Susceptible [5]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S147G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S153A
Missense mutation 1 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S153F
Missense mutation 1.9 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153F.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S153Y+p.L234F
Missense mutation 1.9 Susceptible [5]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153Y, L234F.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S153Y
Missense mutation 2.5 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153Y.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.I72V+p.A98AT+p.L101I+p.G140GS+p.Q148QH+p.K156KN+p.V201I+p.I208L+p.D286DN
Missense mutation 1 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, I72V, A98AT, L101I, G140GS, Q148QH, K156KN, V201I, I208L, D286DN.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.I72V+p.L101I+p.G140S+p.Q148H+p.K156N+p.V201I+p.D207DG+p.I208L
Missense mutation 1 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, I72V, L101I, G140S, Q148H, K156N, V201I, D207DG, I208L.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.I72V+p.L101LI+p.E138EK+p.G140GS+p.Q148QH+p.K156N+p.V201I+p.I208L+p.D286DN
Missense mutation 1 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, I72V, L101LI, E138EK, G140GS, Q148QH, K156N, V201I, I208L, D286DN.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.I72V+p.L101LI+p.E138EK+p.G140GS+p.Q148QH+p.N155ND+p.K156KN+p.V201I+p.I208L+p.D256DE+p.D286DN
Missense mutation 2 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, I72V, L101LI, E138EK, G140GS, Q148QH, N155ND, K156KN, V201I, I208L, D256DE, D286DN.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.I72V+p.L101LI+p.K156N+p.V201I+p.I208L+p.R228RK+p.D286DN
Missense mutation 1 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, I72V, L101LI, K156N, V201I, I208L, R228RK, D286DN.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.S24D+p.S39C+p.L45LQ+p.L101I+p.T124N+p.D167E+p.V201I+p.E212EA+p.R284RG+p.D286N
Missense mutation 1 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, S24D, S39C, L45LQ, L101I, T124N, D167E, V201I, E212EA, R284RG, D286N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.S24D+p.S39C+p.L45LQ+p.L101I+p.T124N+p.G140S+p.Q148H+p.D167E+p.V201I+p.E212A+p.R284G+p.D286N
Missense mutation 3 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, S24D, S39C, L45LQ, L101I, T124N, G140S, Q148H, D167E, V201I, E212A, R284G, D286N.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.V31I+p.E92EQ+p.T97TA+p.L101I+p.T124A+p.Y143R+p.A169AG+p.L234I
Missense mutation 1 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, V31I, E92EQ, T97TA, L101I, T124A, Y143R, A169AG, L234I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.V31I+p.V79VI+p.E92EQ+p.L101I+p.T124A+p.G140GS+p.Q148QR+p.N155NH+p.L234I
Missense mutation 3 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, V31I, V79VI, E92EQ, L101I, T124A, G140GS, Q148QR, N155NH, L234I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.V31I+p.V79VI+p.L101I+p.I113IL+p.T124A+p.K211KR+p.L234I+p.A265AV
Missense mutation 1 Susceptible [4]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S17N, V31I, V79VI, L101I, I113IL, T124A, K211KR, L234I, A265AV.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S24G+p.N155H+p.D253E
Missense mutation 1.5 Susceptible [5]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S24G, N155H, D253E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T122I
Missense mutation 1.1 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T122I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66A
Missense mutation 0.3 Susceptible [13]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.E138K+p.Q148R
Missense mutation 3.3 Susceptible [5]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, E138K, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.E92Q
Missense mutation 0.6 Susceptible [13]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, E92Q.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.N155H
Missense mutation 1.1 Susceptible [13]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.Q148K
Missense mutation 1 Susceptible [5]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, Q148K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.Q148R
Missense mutation 3.4 Susceptible [13]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.R263K
Missense mutation 1.3 Susceptible [5]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, R263K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.S153F
Missense mutation 0.6 Susceptible [5]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, S153F.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I
Missense mutation 0.4 Susceptible [5]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66K
Missense mutation 1.7 Susceptible [13]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A+p.G118R+p.S119R
Missense mutation 0.6 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, G118R, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A+p.G163R
Missense mutation 1.2 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, G163R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A+p.S119G
Missense mutation 0.7 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, S119G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A+p.S119P
Missense mutation 0.6 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, S119P.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A+p.S119R
Missense mutation 1.1 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A+p.S119T
Missense mutation 0.6 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, S119T.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97I
Missense mutation 0.6 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97S
Missense mutation 0.7 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97S.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97V
Missense mutation 0.6 Susceptible [6]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V151A
Missense mutation 0.8 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V151A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V151L
Missense mutation 1.6 Susceptible [12]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V151L.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Y143C
Missense mutation 0.8 Susceptible [13]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Y143C.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Y143H
Missense mutation 0.9 Susceptible [13]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Y143H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Y143R
Missense mutation 1.3 Susceptible [13]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Y143R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.P145S+p.D232N
Missense mutation 0.3 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E227Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.T66I+p.I72V+p.S119P+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 0.3 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E228Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.T66A+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 0.4 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E229Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.T66I+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 0.4 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E230Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.M50I+p.T66I+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 0.4 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E231Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.T66I+p.I72V+p.S123G+p.T124A+p.K127R+p.E157Q+p.D232N
Missense mutation 0.4 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E232Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140C+p.D232N
Missense mutation 0.5 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E233Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146P+p.D232N
Missense mutation 0.5 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E234Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A
Missense mutation 0.6 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E235Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.F121Y
Missense mutation 0.6 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E236Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148K+p.D232N
Missense mutation 0.6 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E237Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148R+p.D232N
Missense mutation 0.6 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E238Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.L68V+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 0.6 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E239Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72A+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 0.6 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E240Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72N+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 0.6 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E241Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M
Missense mutation 0.7 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E242Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.L68I+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 0.7 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E243Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140A+p.D232N
Missense mutation 0.7 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E244Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148H+p.D232N
Missense mutation 0.8 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E245Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E138K+p.D232N
Missense mutation 0.8 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E246Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140S+p.D232N
Missense mutation 0.8 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E247Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146K+p.D232N
Missense mutation 0.8 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E248Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.V151A+p.D232N
Missense mutation 0.8 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E249Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.M50I+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148R+p.D232N
Missense mutation 0.8 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E250Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S119G
Missense mutation 0.9 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E251Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S119P
Missense mutation 0.9 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E252Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Y143C+p.D232N
Missense mutation 0.9 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E253Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72T+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 0.9 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E254Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E138A+p.D232N
Missense mutation 0.9 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E255Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G163K+p.D232N
Missense mutation 0.9 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E256Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S119P+p.S123G+p.T124A+p.K127R+p.Q148R+p.D232N
Missense mutation 0.9 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E257Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148R+p.E157Q+p.D232N
Missense mutation 0.9 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E258Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S119T
Missense mutation 1 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E259Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S147G+p.D232N
Missense mutation 1 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E260Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.Q95R+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 1 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E261Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S119P+p.S123G+p.T124A+p.K127R+p.S147G+p.D232N
Missense mutation 1 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E262Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M50I
Missense mutation 1.1 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E263Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S119R
Missense mutation 1.1 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E264Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G163R
Missense mutation 1.1 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E265Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Y143H+p.D232N
Missense mutation 1.1 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E266Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.Q95K+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 1.1 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E267Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.A128T+p.D232N
Missense mutation 1.1 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E268Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S153A+p.D232N
Missense mutation 1.1 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E269Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E170A+p.D232N
Missense mutation 1.1 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E270Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Y143R+p.D232N
Missense mutation 1.2 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E271Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.H51Y+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 1.2 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E272Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E157Q+p.D232N
Missense mutation 1.2 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E273Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.M50I+p.I72V+p.S123G+p.T124A+p.K127R+p.S147G+p.D232N
Missense mutation 1.2 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E274Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146L+p.D232N
Missense mutation 1.3 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E275Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.M50I+p.I72V+p.E92Q+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 1.3 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E276Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.E92Q+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 1.4 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E277Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.N155H+p.D232N
Missense mutation 1.4 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E278Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146R+p.D232N
Missense mutation 1.4 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E279Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S147G+p.E157Q+p.D232N
Missense mutation 1.4 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E280Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.E92Q+p.S119P+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 1.5 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E281Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.M50I+p.I72V+p.S123G+p.T124A+p.K127R+p.N155H+p.D232N
Missense mutation 1.5 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E282Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.V151L+p.D232N
Missense mutation 1.6 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E283Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E157K+p.D232N
Missense mutation 1.6 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E284Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S119P+p.S123G+p.T124A+p.K127R+p.N155H+p.D232N
Missense mutation 1.6 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E285Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.E92G+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 1.7 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E286Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N+p.R263K
Missense mutation 1.7 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E287Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.N155H+p.E157Q+p.D232N
Missense mutation 1.7 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E288Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.E92Q+p.S123G+p.T124A+p.K127R+p.E157Q+p.D232N
Missense mutation 1.8 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E289Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S153F+p.D232N
Missense mutation 1.9 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E290Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.T66K+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 2.1 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E291Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S153Y+p.D232N
Missense mutation 2.1 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E292Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146I+p.D232N
Missense mutation 2.2 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E293Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140S+p.Q148R+p.D232N
Missense mutation 3.3 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E294Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140S+p.Q148H+p.D232N
Missense mutation 3.3 Susceptible [7]
Sensitive Drug Dolutegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E295Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
References
Ref 1 Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase. J Virol. 2015 Mar;89(6):3163-75. doi: 10.1128/JVI.03353-14. Epub 2014 Dec 31.
Ref 2 Comparable In Vitro Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations. Antimicrob Agents Chemother. 2019 Dec 20;64(1):e01717-19. doi: 10.1128/AAC.01717-19. Print 2019 Dec 20.
Ref 3 Rapid development of high level resistance to dolutegravir with emergence of T97A mutation in two treatment experienced individuals with baseline partial sensitivity to dolutegravir.
Ref 4 The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adultsJ Acquir Immune Defic Syndr. 2012 Nov 1;61(3):297-301. doi: 10.1097/QAI.0b013e31826bfd02.
Ref 5 Integrase Inhibitor Resistance Selections Initiated with Drug Resistant HIV-1.
Ref 6 Bictegravir Resistance Profile: Data for External Experts.
Ref 7 Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-na ve individuals. J Med Virol. 2019 Dec;91(12):2188-2194. doi: 10.1002/jmv.25564. Epub 2019 Aug 20.
Ref 8 Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile. Antimicrob Agents Chemother. 2016 Nov 21;60(12):7086-7097. doi: 10.1128/AAC.01474-16. Print 2016 Dec.
Ref 9 Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. J Antimicrob Chemother. 2015 Feb;70(2):405-11. doi: 10.1093/jac/dku387. Epub 2014 Oct 3.
Ref 10 The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B. AIDS. 2015 Jul 31;29(12):1459-66. doi: 10.1097/QAD.0000000000000752.
Ref 11 Q148N, a Novel Integrase Inhibitor Resistance Mutation Associated with Low-Level Reduction in Elvitegravir Susceptibility. AIDS Res Hum Retroviruses. 2016 Jul;32(7):702-4. doi: 10.1089/AID.2016.0038. Epub 2016 Apr 19.
Ref 12 Pre-existing HIV-1 integrase polymorphisms do not impact treatment response to elvitegravir-containing fixed-dose combination regimens in treatment-naive patients.
Ref 13 Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitnessAntimicrob Agents Chemother. 2013 Jun;57(6):2654-63. doi: 10.1128/AAC.02568-12. Epub 2013 Mar 25.
Ref 14 Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressureRetrovirology. 2013 Feb 22;10:22. doi: 10.1186/1742-4690-10-22.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.